|1.||Parker, William B: 4 articles (08/2012 - 06/2004)|
|2.||Waud, William R: 4 articles (08/2012 - 06/2004)|
|3.||Sorscher, Eric J: 3 articles (08/2012 - 09/2004)|
|4.||Secrist, John A: 3 articles (01/2012 - 06/2004)|
|5.||Johnson, S A: 3 articles (04/2004 - 04/2000)|
|6.||Tollerfield, S M: 3 articles (04/2004 - 04/2000)|
|7.||Or, R: 3 articles (01/2003 - 02/2000)|
|8.||Allan, Paula W: 2 articles (08/2012 - 09/2004)|
|9.||Hong, Jeong S: 2 articles (08/2012 - 09/2004)|
|10.||Maeda, Akinori: 2 articles (08/2009 - 02/2004)|
|1.||B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
04/01/2004 - "This study demonstrates that oral fludarabine phosphate is clinically effective and generally well tolerated by patients with previously untreated B-cell chronic lymphocytic leukemia. "
12/01/1999 - "[Phase II clinical study of SH L 573 (fludarabine phosphate) in patients with chronic lymphocytic leukemia]."
12/01/1996 - "Fludara has been established as the most active single agent in chronic lymphocytic leukemia (CLL) in single arm and comparative clinical trials. "
11/01/1995 - "The study was carried out to investigate the efficacy and toxicity of fludarabine phosphate in the treatment of B-cell chronic lymphocytic leukemia (B-CLL) in previously treated patients. "
07/01/1991 - "In a clinical phase-II study fludarabine phosphate was given to 20 patients with advanced chronic lymphocytic leukemia who had failed on prior conventional therapy. "
|2.||Non-Hodgkin Lymphoma (Lymphosarcoma)
01/01/2006 - "Although intravenous (IV) fludarabine phosphate is effective against indolent B-cell non-Hodgkin's lymphoma (B-NHL), IV administration for 3 to 5 consecutive days is inconvenient in an outpatient setting. "
01/01/1998 - "Long-term remission was registered in patients with low and moderate grade non-Hodgkin's lymphoma, resistant to standard cytostatic treatment, due to the therapeutic synergism of fludara and cytosinarabinoside (FAVAMP)."
02/01/2006 - "The primary objective of this study was to investigate the tolerability, efficacy and pharmacokinetic profile of oral fludarabine phosphate in relapsed patients with indolent B-cell non-Hodgkin's lymphoma (B-NHL). "
02/01/2006 - "Phase I and pharmacokinetic study of oral fludarabine phosphate in relapsed indolent B-cell non-Hodgkin's lymphoma."
01/01/2006 - "Phase II study of oral fludarabine phosphate in relapsed indolent B-Cell non-Hodgkin's lymphoma."
01/01/1986 - "Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity."
01/01/1992 - "Although current treatment protocols are well tolerated, severe neurotoxicity was a consequence of high-dose F-ara-AMP regimens used in early phase I trials against adult acute leukemia. "
11/01/1986 - "Fludarabine phosphate (NSC 312878) infusions for the treatment of acute leukemia: phase I and neuropathological study."
11/01/1986 - "Eleven patients with acute leukemia in relapse received 14 courses of fludarabine phosphate as a 5-day continuous infusion administered at doses of 40 to 100 mg/m2/day. "
01/01/2000 - "A human B-cell CLL model established by transplantation of JOK-1 cells into SCID mice and an anti-leukemia efficacy of fludarabine phosphate."
08/01/2012 - "In vivo antitumor activity of intratumoral fludarabine phosphate in refractory tumors expressing E. "
12/01/2011 - "In vivo, tumor size in the ADV.ARR2PB-PNP/Fludara treatment group was dramatically smaller than in the control groups, and the mice treated with our system had a significantly prolonged survival, with three of eight mice surviving up to the 160-day termination point, as well as no systemic toxicity. "
03/01/2007 - "Intratumoral injection of ACE-PNP, followed by systemically administered fludarabine phosphate, significantly inhibited the growth of pre-established KU-19-19 tumors. "
06/01/2002 - "Transduction of RM1 cells with OAdV220 before implantation in immunocompetent mice dramatically inhibited subcutaneous (s.c.) tumor growth when fludarabine phosphate was administered systemically and increased mouse survival in a dose-dependent manner. "
10/01/1990 - "Pharmacokinetics of 2-F-ara-A (9-beta-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate."
|5.||Waldenstrom Macroglobulinemia (Macroglobulinemia)
01/01/1994 - "A 66-year old female patient with symptomatic Waldenström's macroglobulinemia was treated with six courses of fludarabine monophosphate, which resulted in partial remission of the disease. "
03/01/1994 - "Fludarabine monophosphate and 2Chlorodeoxyadenosine are nucleoside analogues with activity against Waldenström macroglobulinemia. "
02/01/1999 - "Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenström's macroglobulinemia, and mantle-cell lymphoma."
01/01/2002 - "A significant number of chronic lymphocytic leukemia, follicular non-Hodgkin's lymphoma and Waldenström's macroglobulinemia patients, treated with fludarabine phosphate (fludarabine), are elderly with diminished renal function. "
02/01/1993 - "The review of Phase II trials in patients treated by Fludarabine phosphate (Fludara I.V) has been demonstrated to have unequivocal benefit for some patients with Chronic Lymphocytic Leukemia (CLL) non Hodgkin lymphoma and macroglobulinemia. "
|1.||fludarabine monophosphate (Fludara)
|3.||Granulocyte Colony-Stimulating Factor (G-CSF)
|1.||Drug Therapy (Chemotherapy)
|2.||Stem Cell Transplantation
|3.||Transplantation (Transplant Recipients)